Luminex Co. (NASDAQ:LMNX) declared a quarterly dividend on Monday, February 11th, Wall Street Journal reports. Stockholders of record on Thursday, March 21st will be given a dividend of 0.06 per share by the medical instruments supplier on Thursday, April 11th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Wednesday, March 20th.

Luminex has a payout ratio of 44.4% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Luminex to earn $0.53 per share next year, which means the company should continue to be able to cover its $0.24 annual dividend with an expected future payout ratio of 45.3%.

Shares of LMNX stock traded up $0.24 on Monday, reaching $24.86. 220,790 shares of the company were exchanged, compared to its average volume of 297,835. The stock has a market capitalization of $1.10 billion, a PE ratio of 51.73, a price-to-earnings-growth ratio of 5.62 and a beta of 0.81. Luminex has a one year low of $18.62 and a one year high of $35.37.

Luminex (NASDAQ:LMNX) last released its quarterly earnings data on Monday, February 4th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.08). The company had revenue of $81.10 million for the quarter, compared to the consensus estimate of $80.76 million. Luminex had a return on equity of 4.61% and a net margin of 5.81%. Luminex’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period last year, the company earned $0.20 EPS. As a group, research analysts forecast that Luminex will post 0.29 EPS for the current year.

A number of equities research analysts recently weighed in on the stock. BidaskClub upgraded shares of Luminex from a “hold” rating to a “buy” rating in a report on Wednesday, October 31st. ValuEngine upgraded shares of Luminex from a “buy” rating to a “strong-buy” rating in a research note on Monday, October 29th. Zacks Investment Research lowered shares of Luminex from a “hold” rating to a “sell” rating in a research note on Friday, January 18th. Citigroup decreased their price objective on shares of Luminex from $34.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, November 6th. Finally, TheStreet lowered shares of Luminex from a “b-” rating to a “c+” rating in a research note on Friday, December 14th. One analyst has rated the stock with a sell rating, four have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $28.40.

TRADEMARK VIOLATION NOTICE: “Luminex Co. (LMNX) Plans Quarterly Dividend of $0.06” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/02/11/luminex-co-lmnx-plans-quarterly-dividend-of-0-06.html.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Further Reading: How to execute a trade ex-dividend strategy?

Dividend History for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.